Table 3 Treatment regimens for CD and UC patients

Prescribed medications^a, n (%)

 None

8 (3.10)

17 (6.83)

0.04*

1 (0.20)

2 (0.39)

 AZA + INFX

69 (26.74)

9 (3.61)

< 0.01*

7 (1.38)

4 (0.79)

 AZA

64 (24.81)

6 (2.41)

< 0.01*

2 (0.39)

4 (0.79)

 AZA + ADA

23 (8.91)

2 (0.80)

< 0.01*

1 (0.20)

0

 ADA

22 (8.53)

3 (1.20)

< 0.01*

1 (0.20)

1 (0.20)

 INFX

18 (6.20)

0

< 0.01*

1 (0.20)

2 (0.40)

 AZA + mesalazine

14 (5.43)

55 (22.09)

< 0.01*

2 (0.39)

2 (0.39)

 Mesalazine

9 (3.49)

113 (45.38)

< 0.01*

0

7 (1.38)

 AZA + mesalazine + INFX

4 (1.55)

11 (4.42)

0.07

0

0

 AZA + mesalazine + ADA

3 (1.16)

15 (6.02)

< 0.01

0

1 (0.20)

 AZA + SSZ

2 (0.78)

0

0.50

0

0

 Mesalazine + INFX

3 (1.16)

7 (2.81)

0.17

1 (0.20)

2 (0.39)

 Mesalazine + SSZ + UST

1 (0.39)

0

1

0

1(0.20)

 Mesalazine + MTX + AZA

1 (0.39)

0

1

0

0

 ADA + mesalazine

2 (0.78)

3 (1.20)

1

0

1 (0.20)

 Mesalazine + AZA + SSZ

0

1 (0.40)

0.49

0

0

 AZA + SSZ + INF

0

1 (0.40)

0.49

0

0

 Certolizumab + MTX

1 (0.39)

0

1

0

1 (0.20)

 ADA + Mesalazine + 6MP

0

1 (0.40)

0.49

0

0

 AZA + certolizumab

2 (0.78)

0

0.50

0

0

 ADA + MTX

2 (0.78)

0

0.50

0

0

 AZA + vedolizumab

1 (0.39)

0

1

0

1 (0.20)

 Certolizumab

3 (1.16)

0

0.25

0

0

 Ustekinumab

2 (0.78)

0

1

0

1 (0.20)

 AZA + MTX + ADA

1 (0.39)

0

1

0

0

 AZA + UST

1 (0.39)

0

1

0

0

 Vedolizumab + MTX

1 (0.39)

0

1

1 (0.20)

1 (0.20)

 AZA + mesalazine + golimumab

0

1 (0.40)

0.49

0

0

 6MP + mesalazine + vedolizumab

0

1 (0.40)

0.49

1 (0.20)

1 (0.20)

 INFX + MTX

1 (0.39)

0

1

0

0

 SSZ

0

1 (0.40)

0.49

0

0

 Vedolizumab

0

1 (0.40)

0.49

0

0

 Golimumab

0

0

–

0

0

 6MP

0

1 (0.40)

0.49

0

0